ArticleAnnals of medicine2026
Development and validation of a self-management efficacy questionnaire for patients with Fabry disease in China.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regarding: "Development and validation of a self-management efficacy questionnaire for patients with Fabry disease in China".Annals of medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFabry disease (FD) is a rare X-linked lysosomal storage disorder that impacts the quality of life of patients due to its progressive course, the demands of daily self-management, emotional burden and other subjective experiences. This study aimed to assess the self-management efficacy of patients with FD, identify influencing factors and examine the relationship between quality of life and self-management efficacy to support the development of personalized treatment plans.
methodsA cross-sectional study was conducted from March to May 2024 involving 529 patients with FD in China. A clinical assessment tool: the Fabry Disease Self-Management Efficacy Questionnaire (F-SEQ) was developed. Structural validity, internal consistency and test-retest reliability were assessed. Logistic regression analysis was used to identify the factors associated with self-management efficacy.
resultsThe finalized F-SEQ included 42 items and demonstrated good reliability and sensitivity to change. Self-management efficacy scores among patients were moderately low. The total F-SEQ score indicated significant correlations with both the General Self-Efficacy Scale (GSES) and the Study 36-Item Short Form Health Survey. Confidence in medication management was strongly correlated with GSES scores (
conclusionThe F-SEQ is a reliable and valid instrument for assessing self-management efficacy in patients with FD in the Chinese context. It also demonstrated stronger predictive associations with quality-of-life domains than conventional tools, supporting its use in informing personalized intervention strategies aimed at improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.